Shanghai Yutong Pharma, Inc. Approved by SEC to Trade on NASDAQ Over the Counter Bulletin Board Market

NEW YORK, Nov. 13  /PRNewswire-FirstCall/ -- Shanghai Yutong Pharma, Inc. (OTC:SYUP) is pleased to announce that on November 8th, 2006 it has reached the "no further comment" stage with their Form 10-SB filing with the Securities and Exchange Commission.  Pending NASD approval, the company will start trading on the NASDAQ Over the Counter Bulletin Board Market.

About Shanghai Yutong Pharmaceuticals, Inc.

Operating from a 90,000 square foot GMP manufacturing facility in Shanghai PRC, the Company specializes in the development and commercialization of Chinese herbal medicines and biological pharmaceuticals. Legal Disclaimer

The statements contained in this press release contain certain forward looking statements, including statements regarding the company's expectations, intentions, strategies and beliefs regarding the future. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without the control of the company's management.

  For Further Information:
  Rick Oravec
  
  212-924-3548


DATASOURCE: Shanghai Yutong Pharma, Inc.



CONTACT:  Rick Oravec, [phone], , for

Shanghai Yutong Pharma, Inc. 

Copyright